With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.159635-49-1,tert-Butyl 4-methylenepiperidine-1-carboxylate,as a common compound, the synthetic route is as follows.
159635-49-1, m-Chloroperbenzoic acid (1 .14 g, 6.6 mmol) was added to a solution of tert-butyl 4- methylenepiperidine-1-carboxylate (1 g, 5.1 mmol) in CH2CI2(30 ml.) at 0¡ãC. The reaction mixture was stirred for 15 h at rt, diluted with CH2CI2, washed with a saturated aqueous solution of NaHC03and brine, dried (Na2S04), and evaporated to afford 1.1 g of the title compound which was used without further purification. H-NMR (400 MHz, CDCI3) delta ppm 3.74-3.65 (m, 2 H), 3.45-3.38 (m, 2 H), 2.68 (s, 2 H), 1.82-1.75 (m, 2 H), 1.48-1.41 (m, 2 H), 1.46 (s, 9 H).
As the paragraph descriping shows that 159635-49-1 is playing an increasingly important role.
Reference£º
Patent; NOVARTIS AG; FURET, Pascal; GUAGNANO, Vito; HOLZER, Philipp; MAH, Robert; MASUYA, Keiichi; SCHLAPBACH, Achim; STUTZ, Stefan; VAUPEL, Andrea; WO2013/80141; (2013); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem